Clinical Trials Logo

Clinical Trial Summary

A non-comparative randomized phase 2 study, evaluating the efficacy of 5-FU + NALIRI and 5-FU + NALIRINOX for metastatic pancreatic ductal adenocarcinoma (PDAC), progressive after Gemcitabine-Abraxane or Gemcitabine monotherapy


Clinical Trial Description

Based on the results of previous studies, the sponsor aims to assess efficacy and safety of this triplet (irinotecan, 5FU/LV and oxaliplatin) in second-line treatment in fit patients (ECOG 0-1) metastatic PDAC. The primary objective is to assess the efficacy of NALIRINOX (= investigational arm) and NALIRI (= standard care arm) in terms of Progression-Free Survival Rate (PFSR). As secondary objectives, the following will be evaluated in both arms: - Safety/toxicity and tolerability profile according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 5. - Progression free survival (PFS) - Overall response rate and duration of response as assessed by imaging (RECIST 1.1) and tumor markers - Overall survival (OS) ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05472259
Study type Interventional
Source Belgian Group of Digestive Oncology
Contact Lina Dewever
Phone +32 (0) 479 36 63 82
Email lina.dewever@bgdo.org
Status Recruiting
Phase Phase 2
Start date May 25, 2022
Completion date December 31, 2027

See also
  Status Clinical Trial Phase
Active, not recruiting NCT04935359 - Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2 Phase 3
Active, not recruiting NCT05095064 - Retrospective Study on the Efficacy and Tolerability of Liposomal Irinotecan
Active, not recruiting NCT05039177 - A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies Phase 1/Phase 2
Recruiting NCT04888312 - Safety and Efficacy of Mitazalimab in Combination With Chemotherapy in Pancreatic Cancer Patients Phase 1/Phase 2
Terminated NCT04390763 - Study of Efficacy and Safety of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) Phase 2
Not yet recruiting NCT06206876 - FL118 for Treating Patients With Advanced Pancreatic Ductal Adenocarcinoma Phase 1
Recruiting NCT05642962 - Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC) Phase 1/Phase 2
Completed NCT02501902 - Dose-Escalation Study Of Palbociclib + Nab-Paclitaxel In mPDAC Phase 1
Active, not recruiting NCT04581343 - A Phase 1B Study of Canakinumab, Spartalizumab, Nab-paclitaxel, and Gemcitabine in Metastatic PC Patients Phase 1
Completed NCT02558894 - Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma Phase 2
Terminated NCT02732938 - Ph1b/2 Study of PF-04136309 in Combination With Gem/Nab-P in First-line Metastatic Pancreatic Patients Phase 2
Recruiting NCT06445062 - Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors Phase 1/Phase 2
Recruiting NCT02600949 - Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer Phase 1
Recruiting NCT05630183 - A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer Phase 2
Completed NCT02583477 - Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma Phase 1/Phase 2
Terminated NCT04329949 - Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Phase 3
Terminated NCT02101021 - Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Participants With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma Phase 3
Suspended NCT05685602 - CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer Phase 1
Not yet recruiting NCT06398587 - Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma Phase 2
Completed NCT04990037 - A Study of the Safety and Tolerance of CAN04 in Combination With FOLFIRINOX in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma Phase 1